methadone has been researched along with Nicotine Addiction in 41 studies
Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3)
methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.
6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Smoking cessation rates in methadone-maintained smokers are low and novel treatment strategies are required." | 9.17 | Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. ( Anderson, BJ; Audet, D; Caviness, CM; Kurth, ME; Olson, J; Stein, MD, 2013) |
| " Smoking cessation rates in methadone-maintained smokers are low, with men having greater success." | 9.12 | A smoking cessation intervention for the methadone-maintained. ( Anderson, BJ; Anthony, JL; Herman, DS; Niaura, R; Stein, MD; Weinstock, MC, 2006) |
| "To determine predictors of smoking cessation duration in a randomized clinical trial, we assigned participants to nicotine patch (8-12 weeks) plus either (a) a baseline tailored brief motivational intervention, a quit date behavioral skills counseling session, and a relapse prevention follow-up session, or (b) brief advice using the National Cancer Institute's 4A's model." | 9.12 | Smoking cessation patterns in methadone-maintained smokers. ( Anderson, BJ; Niaura, R; Stein, MD, 2007) |
| "To evaluate relapse prevention (relapse prevention) and contingency management (contingency management) for optimizing smoking cessation outcomes using nicotine replacement therapy for methadone-maintained tobacco smokers." | 9.10 | Smoking cessation in methadone maintenance. ( Frosch, D; Jarvik, ME; Ling, W; Nahom, D; Rawson, RA; Rotheram-Fuller, E; Shoptaw, S; Yang, X, 2002) |
| "Individuals in methadone maintenance treatment are motivated to quit smoking and are interested in smoking cessation treatment." | 8.86 | Smoking cessation interventions among individuals in methadone maintenance: a brief review. ( Barr, AM; Greaves, L; Johnson, JL; Khara, M; Okoli, CT; Procyshyn, RM, 2010) |
| "Over 80% of people in methadone treatment smoke cigarettes, and existing smoking cessation interventions have been minimally effective." | 7.81 | Determining Smoking Cessation Related Information, Motivation, and Behavioral Skills among Opiate Dependent Smokers in Methadone Treatment. ( Bernstein, SL; Cooperman, NA; Richter, KP; Steinberg, ML; Williams, JM, 2015) |
| "Smoking cessation treatment service is concerned to be a critical element in methadone maintenance treatment (MMT) in order to diminish the effect of smoke on health outcomes." | 7.81 | Motivation for smoking cessation among drug-using smokers under methadone maintenance treatment in Vietnam. ( Do, HP; Dunne, M; Latkin, C; Nguyen, LH; Nguyen, NP; Phan, HT; Tran, BX, 2015) |
| "The need for research to develop and test tailored interventions for this population is highlighted, as is the need for methadone services and staff to facilitate client smoking cessation." | 7.78 | Smoking cessation among Australian methadone clients: prevalence, characteristics and a need for action. ( Bartlem, K; Bowman, J; Colyvas, K; Walsh, RA; Wiggers, J; Wye, P, 2012) |
| "Patients on methadone should be monitored for signs of methadone toxicity upon the start of smoking cessation, and the dose of methadone should be adjusted accordingly." | 7.77 | Methadone toxicity due to smoking cessation--a case report on the drug-drug interaction involving cytochrome P450 isoenzyme 1A2. ( Kolluru, S; Molina, C; Nguyen, T; Speake, J; Wahawisan, J, 2011) |
| "The aims of this study was to assess the prevalence of lifetime pathological gambling (pathological gambling) and current obsessive compulsive disorder among former heroin addicts currently in methadone maintenance treatment." | 7.75 | Pathological gambling and obsessive compulsive disorder among methadone maintenance treatment patients. ( Adelson, M; Peles, E; Schreiber, S, 2009) |
| " In the 30 days before the survey, respondents reported that their clinics provided the following services to at least one patient: 73 percent provided brief advice to quit, 18 percent offered individual or group smoking cessation counseling, and 12 percent prescribed nicotine replacement therapy." | 7.72 | Smoking cessation services in U.S. methadone maintenance facilities. ( Ahluwalia, JS; Choi, WS; Harris, KJ; McCool, RM; Richter, KP, 2004) |
| "Nicotine use disorder is highly prevalent among methadone maintenance patients with its tobacco-related problems." | 6.58 | Smoking Cessation Among Methadone-Maintained Patients: A Meta-Analysis. ( Hoong, MC; Joyce, YC; Loh, HS; Yee, A, 2018) |
| "Over 85% of opioid-dependent individuals in methadone treatment smoke cigarettes; however, smoking cessation interventions are minimally effective in this population." | 5.27 | Pilot Study of a Tailored Smoking Cessation Intervention for Individuals in Treatment for Opioid Dependence. ( Bernstein, SL; Cooperman, NA; Lu, SE; Richter, KP; Williams, JM, 2018) |
| " Smoking cessation rates in methadone-maintained smokers are low and novel treatment strategies are required." | 5.17 | Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. ( Anderson, BJ; Audet, D; Caviness, CM; Kurth, ME; Olson, J; Stein, MD, 2013) |
| " Smoking cessation rates in methadone-maintained smokers are low, with men having greater success." | 5.12 | A smoking cessation intervention for the methadone-maintained. ( Anderson, BJ; Anthony, JL; Herman, DS; Niaura, R; Stein, MD; Weinstock, MC, 2006) |
| "To determine predictors of smoking cessation duration in a randomized clinical trial, we assigned participants to nicotine patch (8-12 weeks) plus either (a) a baseline tailored brief motivational intervention, a quit date behavioral skills counseling session, and a relapse prevention follow-up session, or (b) brief advice using the National Cancer Institute's 4A's model." | 5.12 | Smoking cessation patterns in methadone-maintained smokers. ( Anderson, BJ; Niaura, R; Stein, MD, 2007) |
| "To evaluate relapse prevention (relapse prevention) and contingency management (contingency management) for optimizing smoking cessation outcomes using nicotine replacement therapy for methadone-maintained tobacco smokers." | 5.10 | Smoking cessation in methadone maintenance. ( Frosch, D; Jarvik, ME; Ling, W; Nahom, D; Rawson, RA; Rotheram-Fuller, E; Shoptaw, S; Yang, X, 2002) |
| "Clonidine's actions and efficacy in mental disorders are reviewed and examined." | 5.06 | Psychiatric indications for clonidine: the neuropharmacologic and clinical basis. ( Bond, WS, 1986) |
| " In the United States there are medications available to treat tobacco use disorders (nicotine replacement, bupropion, and varenicline), alcohol use disorders (naltrexone and acamprosate), and opioid use disorders (methadone and buprenorphine)." | 4.93 | Pharmacotherapy for Substance Use Disorders. ( Klein, JW, 2016) |
| " This review summarizes existing knowledge about smoking cessation treatments for pregnant women on buprenorphine or methadone, the two forms of medication-assisted treatment for opioid use disorder indicated for prenatal use." | 4.91 | Treating tobacco use disorder in pregnant women in medication-assisted treatment for an opioid use disorder: a systematic review. ( Akerman, SC; Blunt, HB; Brunette, MF; Goodman, DJ; Green, AI; Heil, SH, 2015) |
| "Individuals in methadone maintenance treatment are motivated to quit smoking and are interested in smoking cessation treatment." | 4.86 | Smoking cessation interventions among individuals in methadone maintenance: a brief review. ( Barr, AM; Greaves, L; Johnson, JL; Khara, M; Okoli, CT; Procyshyn, RM, 2010) |
| "Over 80% of people in methadone treatment smoke cigarettes, and existing smoking cessation interventions have been minimally effective." | 3.81 | Determining Smoking Cessation Related Information, Motivation, and Behavioral Skills among Opiate Dependent Smokers in Methadone Treatment. ( Bernstein, SL; Cooperman, NA; Richter, KP; Steinberg, ML; Williams, JM, 2015) |
| "Smoking cessation treatment service is concerned to be a critical element in methadone maintenance treatment (MMT) in order to diminish the effect of smoke on health outcomes." | 3.81 | Motivation for smoking cessation among drug-using smokers under methadone maintenance treatment in Vietnam. ( Do, HP; Dunne, M; Latkin, C; Nguyen, LH; Nguyen, NP; Phan, HT; Tran, BX, 2015) |
| "The need for research to develop and test tailored interventions for this population is highlighted, as is the need for methadone services and staff to facilitate client smoking cessation." | 3.78 | Smoking cessation among Australian methadone clients: prevalence, characteristics and a need for action. ( Bartlem, K; Bowman, J; Colyvas, K; Walsh, RA; Wiggers, J; Wye, P, 2012) |
| "Patients on methadone should be monitored for signs of methadone toxicity upon the start of smoking cessation, and the dose of methadone should be adjusted accordingly." | 3.77 | Methadone toxicity due to smoking cessation--a case report on the drug-drug interaction involving cytochrome P450 isoenzyme 1A2. ( Kolluru, S; Molina, C; Nguyen, T; Speake, J; Wahawisan, J, 2011) |
| "The aims of this study was to assess the prevalence of lifetime pathological gambling (pathological gambling) and current obsessive compulsive disorder among former heroin addicts currently in methadone maintenance treatment." | 3.75 | Pathological gambling and obsessive compulsive disorder among methadone maintenance treatment patients. ( Adelson, M; Peles, E; Schreiber, S, 2009) |
| " In multivariate analyses, lower nicotine dependence, prior use of smoking cessation pharmacotherapy, and lower methadone dose were associated with being in the preparation stage." | 3.73 | Cigarette smoking and interest in quitting in methadone maintenance patients. ( Arnsten, J; Li, X; Modali, L; Nahvi, S; Richter, K, 2006) |
| " In the 30 days before the survey, respondents reported that their clinics provided the following services to at least one patient: 73 percent provided brief advice to quit, 18 percent offered individual or group smoking cessation counseling, and 12 percent prescribed nicotine replacement therapy." | 3.72 | Smoking cessation services in U.S. methadone maintenance facilities. ( Ahluwalia, JS; Choi, WS; Harris, KJ; McCool, RM; Richter, KP, 2004) |
| "We describe the degree of nicotine addiction and readiness to quit smoking among people with a history of injection drug use, comparing those in a methadone maintenance treatment program (MMTP) with active illicit drug injectors in a needle exchange program (NEP)." | 3.71 | Interest in smoking cessation among injection drug users. ( Clarke, JG; Gogineni, A; McGarry, KA; Stein, MD, 2001) |
| "Methadone has been shown to increase cigarette smoking in a dose-dependent manner, whereas smoking/nicotine has been shown to increase methadone self-administration and reinforcing properties." | 2.74 | Methadone-nicotine interactions in methadone maintenance treatment patients. ( Brands, B; Elkader, AK; Selby, P; Sproule, BA, 2009) |
| "Intensive treatment for nicotine dependence, environmental interventions, and innovative harm reduction strategies are recommended to address the barriers to quitting observed in this population of pregnant women." | 2.71 | Motivational enhancement therapy for nicotine dependence in methadone-maintained pregnant women. ( Diclemente, C; Haug, NA; Svikis, DS, 2004) |
| "Nicotine use disorder is highly prevalent among methadone maintenance patients with its tobacco-related problems." | 2.58 | Smoking Cessation Among Methadone-Maintained Patients: A Meta-Analysis. ( Hoong, MC; Joyce, YC; Loh, HS; Yee, A, 2018) |
| "The Fagerström test was used to measure nicotine dependence (FTND)." | 1.46 | Factors associated with nicotine dependence during methadone maintenance treatment: findings from a multisite survey in Vietnam. ( Do, HP; Dunne, MP; Latkin, CA; Le, GT; Le, HT; Ngo, C; Nguyen, CT; Nguyen, LH; Nguyen, LK; Phan, HTT; Thi Nguyen, HL; Thi Nguyen, NP; Tran, BX; Tran, TD; Vu, TMT, 2017) |
| "In methadone maintenance treatment programs (MMTPs), 80-90% of participants smoke cigarettes." | 1.39 | Perceived stress and substance use in methadone-maintained smokers. ( Anderson, BJ; Moitra, E; Stein, MD, 2013) |
| "Aims of the present investigation were: (i) to assess the prevalence of current smokers and relative smoking status among a large number of heroin addicts attending opioid-substitution therapy prevalence; (ii) to evaluate the relationship between the type (methadone, buprenorphine) and dosage of opioid substitution therapy and nicotine dependence." | 1.38 | Tobacco addiction and smoking status in heroin addicts under methadone vs. buprenorphine therapy. ( Amen, G; Casari, R; Chiamulera, C; Faccini, M; Lugoboni, F; Moro, L; Pajusco, B; Quaglio, G, 2012) |
| "When methadone and puffs were concurrently available, an increase in methadone's price decreased puff consumption, and demand for methadone was less elastic than when puffs were not concurrently available." | 1.33 | Methadone and nicotine self-administration in humans: a behavioral economic analysis. ( Cowan, K; Hursh, S; Martinetti, MP; Meisch, RA; Spiga, R, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.44) | 18.7374 |
| 1990's | 4 (9.76) | 18.2507 |
| 2000's | 14 (34.15) | 29.6817 |
| 2010's | 22 (53.66) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Do, HP | 2 |
| Nguyen, LH | 2 |
| Thi Nguyen, NP | 1 |
| Ngo, C | 1 |
| Thi Nguyen, HL | 1 |
| Le, GT | 1 |
| Nguyen, LK | 1 |
| Nguyen, CT | 1 |
| Tran, BX | 2 |
| Le, HT | 1 |
| Vu, TMT | 1 |
| Phan, HTT | 1 |
| Tran, TD | 1 |
| Latkin, CA | 1 |
| Dunne, MP | 1 |
| Yee, A | 1 |
| Hoong, MC | 1 |
| Joyce, YC | 1 |
| Loh, HS | 1 |
| Cooperman, NA | 2 |
| Lu, SE | 1 |
| Richter, KP | 5 |
| Bernstein, SL | 2 |
| Williams, JM | 2 |
| Baldassarri, SR | 1 |
| Fiellin, DA | 1 |
| Savage, ME | 1 |
| Madden, LM | 1 |
| Beitel, M | 1 |
| Dhingra, LK | 1 |
| Fucito, L | 1 |
| Camenga, D | 1 |
| Bollampally, P | 1 |
| Barry, DT | 1 |
| Bloom, AJ | 1 |
| Wang, PF | 1 |
| Kharasch, ED | 1 |
| Jordan, CJ | 1 |
| Cao, J | 1 |
| Newman, AH | 1 |
| Xi, ZX | 1 |
| Lin, HC | 1 |
| Chang, YP | 1 |
| Wang, PW | 1 |
| Wu, HC | 1 |
| Yen, CN | 1 |
| Yeh, YC | 1 |
| Chung, KS | 1 |
| Chang, HC | 1 |
| Yen, CF | 1 |
| Stein, MD | 6 |
| Caviness, CM | 1 |
| Kurth, ME | 1 |
| Audet, D | 2 |
| Olson, J | 1 |
| Anderson, BJ | 5 |
| Moitra, E | 1 |
| Steinberg, ML | 1 |
| Akerman, SC | 1 |
| Brunette, MF | 1 |
| Green, AI | 1 |
| Goodman, DJ | 1 |
| Blunt, HB | 1 |
| Heil, SH | 1 |
| Griffin, JL | 1 |
| Segal, KS | 1 |
| Nahvi, S | 2 |
| Nguyen, NP | 1 |
| Phan, HT | 1 |
| Dunne, M | 1 |
| Latkin, C | 1 |
| Caviness, C | 1 |
| Grimone, K | 1 |
| Bailey, GL | 1 |
| Klein, JW | 1 |
| Elkader, AK | 1 |
| Brands, B | 1 |
| Selby, P | 1 |
| Sproule, BA | 1 |
| Epstein, DH | 1 |
| Marrone, GF | 1 |
| Heishman, SJ | 1 |
| Schmittner, J | 1 |
| Preston, KL | 1 |
| Okoli, CT | 1 |
| Khara, M | 1 |
| Procyshyn, RM | 1 |
| Johnson, JL | 1 |
| Barr, AM | 1 |
| Greaves, L | 1 |
| Peles, E | 1 |
| Schreiber, S | 1 |
| Adelson, M | 1 |
| Simkin, DR | 1 |
| Grenoble, S | 1 |
| Reece, AS | 1 |
| Wahawisan, J | 1 |
| Kolluru, S | 1 |
| Nguyen, T | 1 |
| Molina, C | 1 |
| Speake, J | 1 |
| Bowman, J | 1 |
| Wiggers, J | 1 |
| Colyvas, K | 1 |
| Wye, P | 1 |
| Walsh, RA | 1 |
| Bartlem, K | 1 |
| Pajusco, B | 1 |
| Chiamulera, C | 1 |
| Quaglio, G | 1 |
| Moro, L | 1 |
| Casari, R | 1 |
| Amen, G | 1 |
| Faccini, M | 1 |
| Lugoboni, F | 1 |
| Shoptaw, S | 2 |
| Rotheram-Fuller, E | 1 |
| Yang, X | 1 |
| Frosch, D | 1 |
| Nahom, D | 1 |
| Jarvik, ME | 2 |
| Rawson, RA | 2 |
| Ling, W | 2 |
| Auriacombe, M | 1 |
| Fatseas, M | 1 |
| Franques-Rénéric, P | 1 |
| Daulouède, JP | 1 |
| Tignol, J | 1 |
| McCool, RM | 3 |
| Paschall Richter, K | 1 |
| Haug, NA | 1 |
| Svikis, DS | 1 |
| Diclemente, C | 1 |
| Spiga, R | 2 |
| Martinetti, MP | 1 |
| Meisch, RA | 1 |
| Cowan, K | 1 |
| Hursh, S | 1 |
| Choi, WS | 1 |
| Harris, KJ | 1 |
| Ahluwalia, JS | 3 |
| Catley, D | 1 |
| Hall, M | 1 |
| Richter, K | 1 |
| Li, X | 1 |
| Modali, L | 1 |
| Arnsten, J | 1 |
| Weinstock, MC | 1 |
| Herman, DS | 1 |
| Anthony, JL | 1 |
| Niaura, R | 2 |
| Frosch, DL | 1 |
| Schmitz, J | 1 |
| Day, J | 1 |
| Erickson, PG | 1 |
| Kranzler, HR | 1 |
| Amin, H | 1 |
| Modesto-Lowe, V | 1 |
| Oncken, C | 1 |
| Clarke, JG | 1 |
| McGarry, KA | 1 |
| Gogineni, A | 1 |
| Bond, WS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Varenicline Versus Nicotine Replacement for Methadone-Maintained Smokers[NCT00790569] | 315 participants (Actual) | Interventional | 2008-09-30 | Completed | |||
| Effectiveness of an Information-Motivation-Behavioral Skills Model-based Intervention on Adherence to Domiciliary Non-invasive Ventilation of Patients With Chronic Hypercapnic Respiratory Failure: A Randomized Controlled Study[NCT05008211] | 104 participants (Anticipated) | Interventional | 2021-09-16 | Recruiting | |||
| An Innovative Digital Smoking Cessation Intervention for Low-Income Adults With Substance Use Disorder[NCT04419922] | 100 participants (Actual) | Observational | 2020-04-02 | Active, not recruiting | |||
| Telemedicine for Smoking Cessation in Rural Primary Care[NCT00843505] | Phase 3 | 566 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants reporting 7-day abstinence at 6-months, confirmed with CO measurement. (NCT00790569)
Timeframe: 6-Months
| Intervention | participants (Number) |
|---|---|
| Arm I | 5 |
| Arm II | 1 |
| Arm III | 11 |
Change in mean cigarettes per day (NCT00790569)
Timeframe: 6-Months
| Intervention | cigarettes/day (Mean) |
|---|---|
| Arm I | -8.7 |
| Arm II | -8.5 |
| Arm III | -7.8 |
Smoking urges was measured on a 0 (not at all) - 100 (strongest feeling possible) scale. Higher values represent greater urge to smoke. Change in smoking urges was calculated as Follow-up score (6 month) - Baseline Score. (NCT00790569)
Timeframe: 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Arm I | -29.971 |
| Arm II | -25.015 |
| Arm III | -24.177 |
Number of participants reporting 7-day abstinence at 12-months, confirmed with CO measurement. (NCT00790569)
Timeframe: 12 Months
| Intervention | participants (Number) |
|---|---|
| Arm I | 4 |
| Arm II | 1 |
| Arm III | 8 |
Number of participants who self-reported continuous abstinence from their initial quit day (study day 14) to 6 Months (NCT00790569)
Timeframe: 6-Months
| Intervention | participants (Number) |
|---|---|
| Arm I | 2 |
| Arm II | 0 |
| Arm III | 2 |
Reinforcing effects of smoking was measured using the modified version of the Cigarette Evaluation Questionnaire. Participants were asked to indicate on a 12-item scale how smoking made them feel in the prior 30 days on a scale from 1 (Not at all) to 7 (Extremely). Higher values indicated that smoking was a more positive experience for 10 of 12 items. Two items were reverse coded. Change in reinforcing effects of smoking was calculated as Follow-up score (6 month) - Baseline Score. (NCT00790569)
Timeframe: 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Arm I | -1.005 |
| Arm II | -.683 |
| Arm III | -.761 |
Number of participants with self-reported, 7-day abstinence at 6-months (NCT00790569)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Arm I | 11 |
| Arm II | 3 |
| Arm III | 16 |
Number of participants with self-reported 7-day abstinence at 12-months (NCT00790569)
Timeframe: 12 Months
| Intervention | participants (Number) |
|---|---|
| Arm I | 4 |
| Arm II | 3 |
| Arm III | 11 |
Withdrawal Symptoms were measured using a modified version of the Minnesota Behavior Rating Scale. The scale asked subjects to rate their smoking withdrawal symptoms over the previous 24 hours on a scale from 0 (none) to 4 (severe). Higher values indicate more severe withdrawal symptoms. Change in withdrawal symptoms was calculated as Follow-up score (6 month) - Baseline Score. (NCT00790569)
Timeframe: 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Arm I | -.222 |
| Arm II | -.163 |
| Arm III | -.113 |
9 reviews available for methadone and Nicotine Addiction
| Article | Year |
|---|---|
Smoking Cessation Among Methadone-Maintained Patients: A Meta-Analysis.
Topics: Combined Modality Therapy; Humans; Methadone; Opiate Substitution Treatment; Psychotherapy; Smoking | 2018 |
Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.
Topics: Analgesics, Opioid; Buprenorphine; Central Nervous System Stimulants; Cocaine-Related Disorders; Dex | 2019 |
Treating tobacco use disorder in pregnant women in medication-assisted treatment for an opioid use disorder: a systematic review.
Topics: Analgesics, Opioid; Behavior Therapy; Buprenorphine; Female; Humans; Methadone; Opiate Substitution | 2015 |
Pharmacotherapy for Substance Use Disorders.
Topics: Age Factors; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Buprenorphine; Bupropion; Drug T | 2016 |
Smoking cessation interventions among individuals in methadone maintenance: a brief review.
Topics: Female; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; Smoking; Smoking Cessation; So | 2010 |
Pharmacotherapies for adolescent substance use disorders.
Topics: Adolescent; Alcohol Deterrents; Alcoholism; Cocaine-Related Disorders; Disulfiram; Humans; Marijuana | 2010 |
[Substitution therapy in drug addictions].
Topics: Buprenorphine; Ganglionic Stimulants; Heroin Dependence; Humans; Methadone; Narcotics; Nicotine; Pro | 2003 |
Pharmacologic treatments for drug and alcohol dependence.
Topics: Alcohol Deterrents; Alcoholism; Antidepressive Agents; Antipsychotic Agents; Carbamazepine; Cocaine- | 1999 |
A case for addressing cigarette use in methadone and other opioid treatment programs.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders; Prevalence; Psychotherapy, Brief; Regional M | 2000 |
12 trials available for methadone and Nicotine Addiction
| Article | Year |
|---|---|
Pilot Study of a Tailored Smoking Cessation Intervention for Individuals in Treatment for Opioid Dependence.
Topics: Adult; Analgesics, Opioid; Behavior Therapy; Female; Humans; Male; Methadone; Middle Aged; Nicotine; | 2018 |
Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial.
Topics: Adult; Benzazepines; Carbon Monoxide; Female; Follow-Up Studies; Guideline Adherence; Heroin Depende | 2013 |
Barriers to Telephone Quitline Use Among Methadone-Maintained Smokers.
Topics: Adult; Cell Phone; Female; Hotlines; Humans; Male; Methadone; Middle Aged; New York; Opiate Substitu | 2015 |
An Open Trial of Electronic Cigarettes for Smoking Cessation Among Methadone-Maintained Smokers.
Topics: Adult; Electronic Nicotine Delivery Systems; Female; Humans; Male; Methadone; Middle Aged; Opiate Su | 2016 |
Methadone-nicotine interactions in methadone maintenance treatment patients.
Topics: Adult; Double-Blind Method; Drug Interactions; Female; Humans; Male; Methadone; Middle Aged; Narcoti | 2009 |
Smoking cessation in methadone maintenance.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Nicotine; Smoking; | 2002 |
Motivational enhancement therapy for nicotine dependence in methadone-maintained pregnant women.
Topics: Adolescent; Adult; Analysis of Variance; Female; Humans; Linear Models; Methadone; Motivation; Opioi | 2004 |
Dual pharmacotherapy and motivational interviewing for tobacco dependence among drug treatment patients.
Topics: Administration, Topical; Bupropion; Counseling; Dopamine Uptake Inhibitors; Follow-Up Studies; Human | 2005 |
Dual pharmacotherapy and motivational interviewing for tobacco dependence among drug treatment patients.
Topics: Administration, Topical; Bupropion; Counseling; Dopamine Uptake Inhibitors; Follow-Up Studies; Human | 2005 |
Dual pharmacotherapy and motivational interviewing for tobacco dependence among drug treatment patients.
Topics: Administration, Topical; Bupropion; Counseling; Dopamine Uptake Inhibitors; Follow-Up Studies; Human | 2005 |
Dual pharmacotherapy and motivational interviewing for tobacco dependence among drug treatment patients.
Topics: Administration, Topical; Bupropion; Counseling; Dopamine Uptake Inhibitors; Follow-Up Studies; Human | 2005 |
A smoking cessation intervention for the methadone-maintained.
Topics: Adult; Combined Modality Therapy; Female; Humans; Male; Methadone; Middle Aged; Nicotine; Opioid-Rel | 2006 |
Smoking cessation patterns in methadone-maintained smokers.
Topics: Administration, Cutaneous; Adult; Combined Modality Therapy; Confidence Intervals; Female; Humans; M | 2007 |
Effects of nicotine on methadone self-administration in humans.
Topics: Adult; Analysis of Variance; Behavior, Addictive; Carbon Monoxide; Drug Interactions; Female; Heroin | 1998 |
Psychiatric indications for clonidine: the neuropharmacologic and clinical basis.
Topics: Animals; Anxiety; Bipolar Disorder; Clinical Trials as Topic; Clonidine; Double-Blind Method; Drug T | 1986 |
20 other studies available for methadone and Nicotine Addiction
| Article | Year |
|---|---|
Factors associated with nicotine dependence during methadone maintenance treatment: findings from a multisite survey in Vietnam.
Topics: Adult; Alcohol Drinking; Analgesics, Opioid; Cross-Sectional Studies; Developing Countries; Female; | 2017 |
Electronic cigarette and tobacco use in individuals entering methadone or buprenorphine treatment.
Topics: Adult; Buprenorphine; Electronic Nicotine Delivery Systems; Female; Humans; Male; Methadone; Middle | 2019 |
Nicotine oxidation by genetic variants of CYP2B6 and in human brain microsomes.
Topics: Aged; Aged, 80 and over; Brain; Cytochrome P-450 CYP2B6; Female; Humans; Ketamine; Male; Methadone; | 2019 |
Gender differences in heroin users receiving methadone maintenance therapy in Taiwan.
Topics: Adult; Age Factors; Age of Onset; Alcoholism; Areca; Child; Child Rearing; Cross-Sectional Studies; | 2013 |
Perceived stress and substance use in methadone-maintained smokers.
Topics: Adult; Alcoholism; Educational Status; Female; Humans; Logistic Models; Male; Methadone; Narcotics; | 2013 |
Determining Smoking Cessation Related Information, Motivation, and Behavioral Skills among Opiate Dependent Smokers in Methadone Treatment.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Models, Psychological; Motivation; Narcotics; O | 2015 |
Motivation for smoking cessation among drug-using smokers under methadone maintenance treatment in Vietnam.
Topics: Adult; Cross-Sectional Studies; Female; Humans; Male; Methadone; Motivation; Opiate Substitution Tre | 2015 |
Tobacco, cocaine, and heroin: Craving and use during daily life.
Topics: Adult; Behavior, Addictive; Cocaine-Related Disorders; Computers, Handheld; Female; Heroin Dependenc | 2010 |
Pathological gambling and obsessive compulsive disorder among methadone maintenance treatment patients.
Topics: Adult; Age Factors; Cross-Sectional Studies; Female; Gambling; Heroin Dependence; Humans; Male; Meth | 2009 |
Differing age related trajectories of dysfunction in several organ systems in opiate dependence.
Topics: Adult; Aged; Aging; Aging, Premature; Analgesics, Opioid; Disease Progression; Female; Hair Color; H | 2012 |
Methadone toxicity due to smoking cessation--a case report on the drug-drug interaction involving cytochrome P450 isoenzyme 1A2.
Topics: Analgesics, Opioid; Cytochrome P-450 CYP1A2; Dose-Response Relationship, Drug; Drug Interactions; Hu | 2011 |
Smoking cessation among Australian methadone clients: prevalence, characteristics and a need for action.
Topics: Adult; Australia; Cross-Sectional Studies; Female; Heroin Dependence; Humans; Male; Methadone; Motiv | 2012 |
Tobacco addiction and smoking status in heroin addicts under methadone vs. buprenorphine therapy.
Topics: Adult; Buprenorphine; Female; Heroin Dependence; Humans; Italy; Male; Methadone; Narcotic Antagonist | 2012 |
Why do so many drug users smoke?
Topics: Adult; Causality; Comorbidity; Cross-Sectional Studies; Female; Focus Groups; Health Surveys; Heroin | 2003 |
Methadone and nicotine self-administration in humans: a behavioral economic analysis.
Topics: Adult; Choice Behavior; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interac | 2005 |
Smoking cessation services in U.S. methadone maintenance facilities.
Topics: Adult; Combined Modality Therapy; Comorbidity; Counseling; Cross-Sectional Studies; Female; Health S | 2004 |
Cigarette smoking and interest in quitting in methadone maintenance patients.
Topics: Adult; Aged; Cross-Sectional Studies; Drug Administration Schedule; Female; Health Care Surveys; Hum | 2006 |
Interest in smoking cessation among methadone maintained outpatients.
Topics: Adult; Ambulatory Care; Analgesics, Opioid; Female; Humans; Male; Marijuana Abuse; Methadone; Motiva | 1998 |
Introduction: the three phases of harm reduction. An examination of emerging concepts, methodologies, and critiques.
Topics: Acquired Immunodeficiency Syndrome; Alcoholism; Canada; Community-Institutional Relations; Cost of I | 1999 |
Interest in smoking cessation among injection drug users.
Topics: Adult; Female; Humans; Male; Methadone; Motivation; Narcotic Antagonists; Smoking Cessation; Substan | 2001 |